11636results about "Animals/human peptides" patented technology

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

To provide methods for treating a subject having or at risk of developing a neurocognitive disorder, such as frontotemporal lobar degeneration or neuronal ceroid lipofuscinosis.SOLUTION: Provided is a method comprising administering, to a subject diagnosed as having a neurocognitive disorder (NCD), a composition comprising a population of cells comprising a transgene encoding a progranulin (PGRN) or a granulin (GRN).SELECTED DRAWING: Figure 1A

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Among other things, the present disclosure provides oligonucleotide compositions and methods thereof. In some embodiments, oligonucleotides comprise various chemical modifications of sugars, nucleobases, and / or internucleotidic linkages and patterns thereof and are useful for exon skipping. In some embodiments, the present disclosure provides technologies useful for skipping exon 44 of dystrophin (DMD) transcripts. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, the present disclosure provides methods for preventing or treating conditions, disorders or diseases including Duchenne muscular dystrophy.

The invention discloses a site for stably expressing protein in a CHO cell gene NW023276806.1 and application of the site, and belongs to the technical field of biological genes. The site belongs to a fixed position in a CHO cell genome, different protein genes are introduced based on a micro-homologous end connection mechanism through a CRISPR / Cas9 tool, and stable expression is carried out. By adopting a site-specific integration method, a target gene is integrated to a stable expression area in a site-specific manner, repeated high-expression monoclonal screening is effectively avoided, and an MMEJ mechanism is introduced to integrate a donor fragment, so that the research and development time for constructing a stable expression cell strain in biological pharmacy can be effectively shortened, and the cost is reduced.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

The present invention provides a method for packaging a BaEV retroviral vector. The method includes constructing a stable BaEV retroviral packaging cell line, transfecting a retroviral vector plasmid containing a target sequence into a virus-producing cell line, where the virus-producing cell line is a HEK293T cell line or its derivative cell line, to harvest the transiently transfected and virus-producing retroviral vector, mixing it with the stable BaEV retroviral packaging cell line, and promoting the transduction of the retroviral vector into the stable BaEV retroviral packaging cell line by horizontal centrifugation. The present invention can achieve the packaging of a BAEV-type retroviral vector carrying a CD19CAR foreign gene plasmid, construct a BAEV-type retroviral vector-producing cell line, and produce a high-titer BAEV-type retroviral vector.

The invention discloses tetrapeptide KA4 with an anti-fatigue function as well as a preparation method and application of the tetrapeptide KA4, and belongs to the technical field of biology. The tetrapeptide KA4 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is KYPA, and the tetrapeptide KA4 has strong binding capacity with KEAP1, AMPK and LDH, can significantly reduce the serum lactic acid content of a fatigue model mouse and significantly increase the load swimming time of the fatigue model mouse, has an anti-fatigue function, and can be applied to development of functional food for relieving fatigue.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to enhance production yield and fruit quality of cucumber by selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and, at early growth stage, applied to the soil around and / or leaf surface of the cucumber plants. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, before administering as taught herein.

The invention relates to a stable silk fibroin liquid condensation body, gel and a preparation method and application thereof, and belongs to the technical field of silk fibroin. The preparation method comprises the following steps: S1, dissolving silk fibroin in a lithium bromide solution, and then adding trypsin for incubation to obtain an enzyme-digested silk fibroin solution; and S2, performing low-temperature programmed centrifugal treatment including an induction stage, a nucleation stage and a liquid-liquid phase separation stage on the enzyme-digested silk fibroin solution, and cleaning to obtain the stable silk fibroin liquid-state aggregate, the method can reduce aggregate liquid drop aggregation and improve the particle size uniformity of the liquid drops.

The invention provides a recombinant keratin polypeptide as well as a preparation method and application thereof, and relates to the technical field of genetic engineering. The amino acid sequence of the recombinant keratin polypeptide is as shown in any one of SEQ ID No. 1, SEQ ID No. 4, SEQ ID No. 7 and SEQ ID No. 10. The recombinant keratin polypeptide has a good soothing effect and the effects of stimulating skin angiogenesis and improving local blood circulation, and can be widely applied to the industries of medicines, cosmetics, skin care products and the like.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to promote the growth and development of corn crops, by selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and, at seedling stage and / or early growth stage, applied to the soil around or sprayed to the young plants. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, before administering as taught herein.

The invention discloses a peptide with a bone strengthening effect as well as a preparation method and application thereof, and relates to the field of biology. The casein is used as a raw material, the high-activity calcium ion chelating peptide and the directional preparation technology thereof are provided, the technology has the advantages of being high in efficiency, low in cost, easy to operate, good in stability and the like, the high-activity calcium ion chelating peptide can be prepared on a large scale, the utilization value of the casein is improved, and a new way is provided for development of functional natural calcium supplement products.

The invention relates to a silk fibroin biological material with high beta-fold content and a preparation method thereof, and belongs to the technical field of biological extraction. The method comprises the following steps: preparing a regenerated silk fibroin solution; adding an enzyme catalytic promoter and an enzyme into the regenerated silk fibroin solution for incubation; the enzyme catalysis auxiliary agent is selected from one or more of a metal ion catalyst, a zwitterionic surfactant, a functionalized ionic liquid and a calcium phosphate nano-cluster; and centrifuging, cleaning and drying the obtained product to obtain the silk fibroin biological material with high beta-fold content. The silk fibroin material has higher beta-folding amount through primary structure modification, the space structure is more crystallized, and the amino acid sequence is more regular and ordered. The silk fibroin material provided by the invention has excellent mechanical properties, efficiency and yield, and is a biological protein material with great development potential.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to enhance the drought tolerance attribute of wheat plants. By selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then infused to the soil in which the wheat seeds are planted; the solution can also be sprayed to the leaf surface of young wheat plants. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, for applying to the soil around the wheat plants and for spraying to leaf surface of young wheat plants.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to improve the efficacy of fertilizer usage and absorption by soybeans. By selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then infused to the fertilized soil in which the soybean seeds are grown, as well as the plants after the seed start sprouting. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, for applying to the soil around the soybean.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

The present invention addresses the problem of providing a male fish individual having low aggressiveness. The present invention also address the problem of providing a male fish individual having higher growth efficiency. The present invention provides a male fish individual having suppressed functional expression of CYP19a1b (cytochrome P450, family 19, subfamily A, polypeptide 1b).

The invention discloses a protein separation method and related application thereof, and relates to the technical field of dairy product processing, the method comprises the following steps: heating a whey solution of which the pH value is adjusted to 3.5-4.2 by a citric acid solution, carrying out microfiltration on the heated product, carrying out beta-lactoglobulin and / or alpha-lactalbumin separation on permeate and trapped fluid obtained by microfiltration, the method is based on the membrane filtration technology, high-purity separation of beta-lactoglobulin and alpha-lactalbumin is achieved, the purity can reach 70%-90% or above, the method is compatible with whey from multiple sources, equipment is simple, the method has the advantages of being low in separation cost, high in efficiency, easy to implement, large in flux and the like, and a way is provided for large-scale industrial production of beta-lactoglobulin and alpha-lactalbumin.

The invention relates to a protein-based phenylboronic acid ester dynamic crosslinking hydrogel material as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving a component A, namely a phenylboronic acid modified protein polymer derivative, in a biocompatible medium to obtain a solution A; dissolving a component B, namely a macromolecular derivative containing a vicinal diol group, into a biocompatible medium to obtain a solution B; and mixing the solution A and the solution B with a certain concentration for a certain time to obtain the protein-based phenylboronic acid ester dynamic crosslinking hydrogel material. The boric acid ester dynamic cross-linking bond belongs to reversible chemical cross-linking reaction, and the prepared protein-based hydrogel material has enough mechanical strength and cheap operability. The protein-based hydrogel material disclosed by the invention can provide the effects of cell adhesion, proliferation and differentiation promotion, tissue regeneration and the like, can load and slowly release beneficial components for promoting tissue repair, is an ideal tissue engineering scaffold material, and can be applied to defect regeneration and repair of soft tissues, cartilages, bones and the like.

A method for visible light-mediated chemical modification of a polypeptide or protein based on cysteine includes the following steps: allowing a cysteine residue on a cysteine-containing oligopeptide, polypeptide, or protein to undergo a reaction with an activating reagent to generate a free radical precursor in situ; and subjecting the free radical precursor to desulfurization under photocatalytic condition, and allowing the generated free radical intermediate to undergo an addition reaction with an olefin or an alkyne, such that sulfhydryl removal and carbon-carbon bond construction are achieved to produce a chemical modification product of the polypeptide and protein. The method cleverly avoids the influence on the chiral center, and thus the chirality of the amino acid residue can be retained. The method is conducive to well avoiding the occurrence of side reactions, and thus the efficiency of the entire conversion is very high.

The invention relates to the technical field of coating surface preparation, in particular to an anticoagulant coating based on novel tick-derived anticoagulant protein Qinghaenin and a preparation method of the anticoagulant coating. The functional layer of the anticoagulant coating comprises the following components: anticoagulant protein Qinghaenin or a functional peptide fragment Qinghaenin 167-192 of the anticoagulant protein Qinghaenin, wherein the amino acid sequence of the functional peptide fragment is as shown in SEQ ID NO. 2. The preparation method of the anticoagulant coating comprises the following steps: by using a polydopamine coating as a substrate layer, covalently grafting through an amido bond, immobilizing anticoagulant protein Qinghaenin capable of inhibiting FXII factor activation or a functional peptide fragment Qinghaenin 167-192 thereof on the surface of a medical polymer material, and successfully constructing a novel anticoagulant coating. Compared with an unmodified medical polymer material, the modified coating can significantly enhance the hydrophilic performance of the material and inhibit platelet adhesion and activation, finally effectively prolongs the in-vitro blood coagulation time, and shows excellent anticoagulation performance.

A method for separating protein from a milk raw material, the method comprising separating beta-lactoglobulin and alpha-lactalbumin from the milk raw material, the method comprising: a whey separation step for separating whey protein from the milk raw material; a step of ion exchange treatment: adsorbing the whey protein by using strong anion exchange resin, then eluting by using an eluent, adsorbing the whey protein by using strong anion exchange resin to obtain a flow-through liquid, enriching alpha-lactalbumin in the flow-through liquid, and carrying out gradient elution by using the eluent to obtain an elution component, at least one of the elution components is enriched with beta-lactoglobulin; and purifying the flow-through liquid to obtain an alpha-lactalbumin solid, and purifying the elution component enriched with beta-lactoglobulin to obtain a beta-lactoglobulin solid.

Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of CRISPR systems and non-LTR retrotransposon elements.

The invention relates to the technical field of biological medicine, in particular to cat allergen fusion protein, an mRNA immune preparation and application of the cat allergen fusion protein and the mRNA immune preparation. The amino acid sequence of the cat allergen fusion protein disclosed by the invention is as shown in SEQ ID NO.11. The cat allergen fusion protein provided by the invention is a fusion protein obtained by fusing key segments with strong sensitization of Fel d2 and Fel d4 proteins with Fel d1 full-length protein, the fusion protein can simultaneously cover main sensitization epitopes of Fel d1, Fel d2 and Fel d4, and the sensitization effect of cat allergens can be more comprehensively blocked. According to the cat allergen fusion protein provided by the invention, an mRNA immune preparation can be rapidly designed and synthesized, the expression of the cat allergen fusion protein can be accurately controlled in poultry bodies, the immunoreaction is more durable, and the prepared IgY antibody can effectively block allergic protein in cat oral saliva.

Disclosed herein are compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.